Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008

Ovarian Neoplasms

Free Subscription Articles published in Cancer Res Retrieve available abstracts of 111 articles: HTML format

Single Articles

June 2008
1. ABEDINI MR , Muller EJ, Brun J, Bergeron R, et al
   Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells.
   Cancer Res. 2008;68:4511-7.
   PubMed     Related articles    Abstract available
   
   
   
2. ZHANG S , Balch C, Chan MW, Lai HC, et al
   Identification and characterization of ovarian cancer-initiating cells from primary human tumors.
   Cancer Res. 2008;68:4311-20.
   PubMed     Related articles    Abstract available
   
   
   April 2008
3. BASU A , Adkins B, Basu C
   Down-regulation of caspase-2 by rottlerin via protein kinase C-delta-independent pathway.
   Cancer Res. 2008;68:2795-802.
   PubMed     Related articles    Abstract available
   
   
   
4. SWISHER EM , Sakai W, Karlan BY, Wurz K, et al
   Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.
   Cancer Res. 2008;68:2581-6.
   PubMed     Related articles    Abstract available
   
   
   
5. KELEMEN LE , Sellers TA, Schildkraut JM, Cunningham JM, et al
   Genetic variation in the one-carbon transfer pathway and ovarian cancer risk.
   Cancer Res. 2008;68:2498-506.
   PubMed     Related articles    Abstract available
   
   
   
6. SAWADA K , Mitra AK, Radjabi AR, Bhaskar V, et al
   Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.
   Cancer Res. 2008;68:2329-39.
   PubMed     Related articles    Abstract available
   
   
   
7. LOTAN T , Hickson J, Souris J, Huo D, et al
   c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation.
   Cancer Res. 2008;68:2166-75.
   PubMed     Related articles    Abstract available
   
   
   February 2008
8. JEON BH , Jang C, Han J, Kataru RP, et al
   Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer.
   Cancer Res. 2008;68:1100-9.
   PubMed     Related articles    Abstract available
   
   
   
9. POTAPOVA A , Hoffman AM, Godwin AK, Al-Saleem T, et al
   Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
   Cancer Res. 2008;68:998-1002.
   PubMed     Related articles    Abstract available
   
   
   
10. ZECCHINI S , Bianchi M, Colombo N, Fasani R, et al
    The differential role of L1 in ovarian carcinoma and normal ovarian surface epithelium.
    Cancer Res. 2008;68:1110-8.
    PubMed     Related articles    Abstract available
    
    
    
11. KLINCK R , Bramard A, Inkel L, Dufresne-Martin G, et al
    Multiple alternative splicing markers for ovarian cancer.
    Cancer Res. 2008;68:657-63.
    PubMed     Related articles    Abstract available
    
    
    January 2008
12. YANG H , Kong W, He L, Zhao JJ, et al
    MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN.
    Cancer Res. 2008;68:425-33.
    PubMed     Related articles    Abstract available
    
    
    
13. KONG X , Wang X, Xu W, Behera S, et al
    Natriuretic peptide receptor a as a novel anticancer target.
    Cancer Res. 2008;68:249-56.
    PubMed     Related articles    Abstract available
    
    
    December 2007
14. WANG J , Zhou JY, Wu GS
    ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells.
    Cancer Res. 2007;67:11933-41.
    PubMed     Related articles    Abstract available
    
    
    
15. LI L , Ryser S, Dizin E, Pils D, et al
    Oncogenic BARD1 isoforms expressed in gynecological cancers.
    Cancer Res. 2007;67:11876-85.
    PubMed     Related articles    Abstract available
    
    
    
16. GAITHER A , Porter D, Yao Y, Borawski J, et al
    A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signaling.
    Cancer Res. 2007;67:11493-8.
    PubMed     Related articles    Abstract available
    
    
    November 2007
17. YOKOYAMA Y , Sedgewick G, Ramakrishnan S
    Endostatin Binding to Ovarian Cancer Cells Inhibits Peritoneal Attachment and Dissemination.
    Cancer Res. 2007;67:10813-10822.
    PubMed     Related articles    Abstract available
    
    
    
18. HALDER J , Lin YG, Merritt WM, Spannuth WA, et al
    Therapeutic Efficacy of a Novel Focal Adhesion Kinase Inhibitor TAE226 in Ovarian Carcinoma.
    Cancer Res. 2007;67:10976-10983.
    PubMed     Related articles    Abstract available
    
    
    
19. LANDEN CN JR , Lin YG, Armaiz Pena GN, Das PD, et al
    Neuroendocrine Modulation of Signal Transducer and Activator of Transcription-3 in Ovarian Cancer.
    Cancer Res. 2007;67:10389-10396.
    PubMed     Related articles    Abstract available
    
    
    
20. LU L , Katsaros D, Rigault de la Longrais IA, Sochirca O, et al
    Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis.
    Cancer Res. 2007;67:10117-10122.
    PubMed     Related articles    Abstract available
    
    
    October 2007
21. CHANG CL , Tsai YC, He L, Wu TC, et al
    Cancer immunotherapy using irradiated tumor cells secreting heat shock protein 70.
    Cancer Res. 2007;67:10047-57.
    PubMed     Related articles    Abstract available
    
    
    
22. RAVIKUMAR S , Perez-Liz G, Del Vale L, Soprano DR, et al
    Insulin Receptor Substrate-1 Is an Important Mediator of Ovarian Cancer Cell Growth Suppression by All-trans Retinoic Acid.
    Cancer Res. 2007;67:9266-75.
    PubMed     Related articles    Abstract available
    
    
    
23. KIM TJ , Ravoori M, Landen CN, Kamat AA, et al
    Antitumor and Antivascular Effects of AVE8062 in Ovarian Carcinoma.
    Cancer Res. 2007;67:9337-45.
    PubMed     Related articles    Abstract available
    
    
    
24. GRANOT D , Addadi Y, Kalchenko V, Harmelin A, et al
    In vivo Imaging of the Systemic Recruitment of Fibroblasts to the Angiogenic Rim of Ovarian Carcinoma Tumors.
    Cancer Res. 2007;67:9180-9.
    PubMed     Related articles    Abstract available
    
    
    September 2007
25. IORIO MV , Visone R, Di Leva G, Donati V, et al
    MicroRNA Signatures in Human Ovarian Cancer.
    Cancer Res. 2007;67:8699-8707.
    PubMed     Related articles    Abstract available
    
    
    
26. KRYCZEK I , Wei S, Zhu G, Myers L, et al
    Relationship between B7-H4, Regulatory T Cells, and Patient Outcome in Human Ovarian Carcinoma.
    Cancer Res. 2007;67:8900-5.
    PubMed     Related articles    Abstract available
    
    
    
27. STAVENHAGEN JB , Gorlatov S, Tuaillon N, Rankin CT, et al
    Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
    Cancer Res. 2007;67:8882-90.
    PubMed     Related articles    Abstract available
    
    
    
28. LI X , Shen L, Zhang J, Su J, et al
    Degradation of HER2 by Cbl-based chimeric ubiquitin ligases.
    Cancer Res. 2007;67:8716-24.
    PubMed     Related articles    Abstract available
    
    
    
29. CORNEY DC , Flesken-Nikitin A, Godwin AK, Wang W, et al
    MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth.
    Cancer Res. 2007;67:8433-8.
    PubMed     Related articles    Abstract available
    
    
    
30. TSUDA N , Chang DZ, Mine T, Efferson C, et al
    Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells.
    Cancer Res. 2007;67:8378-87.
    PubMed     Related articles    Abstract available
    
    
    August 2007
31. KIKUCHI R , Tsuda H, Kanai Y, Kasamatsu T, et al
    Promoter Hypermethylation Contributes to Frequent Inactivation of a Putative Conditional Tumor Suppressor Gene Connective Tissue Growth Factor in Ovarian Cancer.
    Cancer Res. 2007;67:7095-7105.
    PubMed     Related articles    Abstract available
    
    
    
32. WEI S , Kryczek I, Edwards RP, Zou L, et al
    Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma.
    Cancer Res. 2007;67:7487-94.
    PubMed     Related articles    Abstract available
    
    
    
33. LI B , Allendorf DJ, Hansen R, Marroquin J, et al
    Combined yeast {beta}-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55.
    Cancer Res. 2007;67:7421-30.
    PubMed     Related articles    Abstract available
    
    
    
34. JACQUEMONT C , Taniguchi T
    Proteasome function is required for DNA damage response and fanconi anemia pathway activation.
    Cancer Res. 2007;67:7395-405.
    PubMed     Related articles    Abstract available
    
    
    
35. SATPATHY M , Cao L, Pincheira R, Emerson R, et al
    Enhanced peritoneal ovarian tumor dissemination by tissue transglutaminase.
    Cancer Res. 2007;67:7194-202.
    PubMed     Related articles    Abstract available
    
    
    July 2007
36. ROSANO L , Di Castro V, Spinella F, Tortora G, et al
    Combined targeting of endothelin a receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
    Cancer Res. 2007;67:6351-9.
    PubMed     Related articles    Abstract available
    
    
    
37. VENERE M , Snyder A, Zgheib O, Halazonetis TD, et al
    Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.
    Cancer Res. 2007;67:6100-5.
    PubMed     Related articles    Abstract available
    
    
    June 2007
38. ROBINSON-SMITH TM , Isaacsohn I, Mercer CA, Zhou M, et al
    Macrophages mediate inflammation-enhanced metastasis of ovarian tumors in mice.
    Cancer Res. 2007;67:5708-16.
    PubMed     Related articles    Abstract available
    
    
    
39. DAIKOKU T , Tranguch S, Chakrabarty A, Wang D, et al
    Extracellular Signal-Regulated Kinase Is a Target of Cyclooxygenase-1-Peroxisome Proliferator-Activated Receptor-{delta} Signaling in Epithelial Ovarian Cancer.
    Cancer Res. 2007;67:5285-92.
    PubMed     Related articles    Abstract available
    
    
    May 2007
40. HEMPEL N , How T, Dong M, Murphy SK, et al
    Loss of Betaglycan Expression in Ovarian Cancer: Role in Motility and Invasion.
    Cancer Res. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
41. BARBER A , Zhang T, Demars LR, Conejo-Garcia J, et al
    Chimeric NKG2D Receptor-Bearing T Cells as Immunotherapy for Ovarian Cancer.
    Cancer Res. 2007;67:5003-8.
    PubMed     Related articles    Abstract available
    
    
    
42. CHEN Y , Clark S, Wong T, Chen Y, et al
    Armed Antibodies Targeting the Mucin Repeats of the Ovarian Cancer Antigen, MUC16, Are Highly Efficacious in Animal Tumor Models.
    Cancer Res. 2007;67:4924-32.
    PubMed     Related articles    Abstract available
    
    
    
43. VAN VLERKEN LE , Duan Z, Seiden MV, Amiji MM, et al
    Modulation of intracellular ceramide using polymeric nanoparticles to overcome multidrug resistance in cancer.
    Cancer Res. 2007;67:4843-50.
    PubMed     Related articles    Abstract available
    
    
    
44. BAK SP , Walters JJ, Takeya M, Conejo-Garcia JR, et al
    Scavenger receptor-a-targeted leukocyte depletion inhibits peritoneal ovarian tumor progression.
    Cancer Res. 2007;67:4783-9.
    PubMed     Related articles    Abstract available
    
    
    
45. PETROCCA F , Calin GA, Croce CM
    ARLTS1 Trp149Stop Mutation and the Risk of Ovarian Cancer.
    Cancer Res. 2007;67:4534.
    PubMed     Related articles   
    
    
    
46. MASOJC B , Medrek K, Debniak T, Lubinski J, et al
    ARLTS1 Trp149Stop Mutation and the Risk of Ovarian Cancer.
    Cancer Res. 2007;67:4533.
    PubMed     Related articles   
    
    
    
47. DARCY KM , Tian C, Reed E
    A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy.
    Cancer Res. 2007;67:4474-81.
    PubMed     Related articles    Abstract available
    
    
    April 2007
48. SCHUMACHER JJ , Dings RP, Cosin J, Subramanian IV, et al
    Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells.
    Cancer Res. 2007;67:3683-90.
    PubMed     Related articles    Abstract available
    
    
    
49. MALONEY A , Clarke PA, Naaby-Hansen S, Stein R, et al
    Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Cancer Res. 2007;67:3239-53.
    PubMed     Related articles    Abstract available
    
    
    
50. NANJUNDAN M , Nakayama Y, Cheng KW, Lahad J, et al
    Amplification of MDS1/EVI1 and EVI1, Located in the 3q26.2 Amplicon, Is Associated with Favorable Patient Prognosis in Ovarian Cancer.
    Cancer Res. 2007;67:3074-84.
    PubMed     Related articles    Abstract available
    
    
    
51. GAYTHER SA , Song H, Ramus SJ, Kjaer SK, et al
    Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer.
    Cancer Res. 2007;67:3027-35.
    PubMed     Related articles    Abstract available
    
    
    
52. ZHOU W , Han WF, Landree LE, Thupari JN, et al
    Fatty Acid Synthase Inhibition Activates AMP-Activated Protein Kinase in SKOV3 Human Ovarian Cancer Cells.
    Cancer Res. 2007;67:2964-71.
    PubMed     Related articles    Abstract available
    
    
    
53. BEHBAKHT K , Qamar L, Aldridge CS, Coletta RD, et al
    Six1 overexpression in ovarian carcinoma causes resistance to TRAIL-mediated apoptosis and is associated with poor survival.
    Cancer Res. 2007;67:3036-42.
    PubMed     Related articles    Abstract available
    
    
    March 2007
54. SWISHER EM , King MC
    Defining women at high risk of ovarian cancer.
    Cancer Res. 2007;67:2902.
    PubMed     Related articles   
    
    
    
55. BAGBY GC , Pejovic T
    Defining women at high risk of ovarian cancer.
    Cancer Res. 2007;67:2902-3.
    PubMed     Related articles   
    
    
    
56. MABUCHI S , Altomare DA, Connolly DC, Klein-Szanto A, et al
    RAD001 (Everolimus) Delays Tumor Onset and Progression in a Transgenic Mouse Model of Ovarian Cancer.
    Cancer Res. 2007;67:2408-13.
    PubMed     Related articles    Abstract available
    
    
    
57. HAMA Y , Urano Y, Koyama Y, Kamiya M, et al
    A target cell-specific activatable fluorescence probe for in vivo molecular imaging of cancer based on a self-quenched avidin-rhodamine conjugate.
    Cancer Res. 2007;67:2791-9.
    PubMed     Related articles    Abstract available
    
    
    
58. TOLMACHEV V , Orlova A, Pehrson R, Galli J, et al
    Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
    Cancer Res. 2007;67:2773-82.
    PubMed     Related articles    Abstract available
    
    
    
59. JACOBS S , Thompson ER, Nannya Y, Yamamoto G, et al
    Genome-wide, high-resolution detection of copy number, loss of heterozygosity, and genotypes from formalin-fixed, paraffin-embedded tumor tissue using microarrays.
    Cancer Res. 2007;67:2544-51.
    PubMed     Related articles    Abstract available
    
    
    
60. ORLOVA A , Tolmachev V, Pehrson R, Lindborg M, et al
    Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors.
    Cancer Res. 2007;67:2178-86.
    PubMed     Related articles    Abstract available
    
    
    
61. SYMOWICZ J , Adley BP, Gleason KJ, Johnson JJ, et al
    Engagement of collagen-binding integrins promotes matrix metalloproteinase-9-dependent E-cadherin ectodomain shedding in ovarian carcinoma cells.
    Cancer Res. 2007;67:2030-9.
    PubMed     Related articles    Abstract available
    
    
    
62. MORENO-BUENO G , Fernandez-Marcos PJ, Collado M, Tendero MJ, et al
    Inactivation of the candidate tumor suppressor par-4 in endometrial cancer.
    Cancer Res. 2007;67:1927-34.
    PubMed     Related articles    Abstract available
    
    
    February 2007
63. ALBANITO L , Madeo A, Lappano R, Vivacqua A, et al
    G Protein-Coupled Receptor 30 (GPR30) Mediates Gene Expression Changes and Growth Response to 17{beta}-Estradiol and Selective GPR30 Ligand G-1 in Ovarian Cancer Cells.
    Cancer Res. 2007;67:1859-1866.
    PubMed     Related articles    Abstract available
    
    
    
64. FISTER S , Gunthert AR, Emons G, Grundker C, et al
    Gonadotropin-Releasing Hormone Type II Antagonists Induce Apoptotic Cell Death in Human Endometrial and Ovarian Cancer Cells In vitro and In vivo.
    Cancer Res. 2007;67:1750-6.
    PubMed     Related articles    Abstract available
    
    
    
65. SAWADA K , Radjabi AR, Shinomiya N, Kistner E, et al
    c-Met Overexpression Is a Prognostic Factor in Ovarian Cancer and an Effective Target for Inhibition of Peritoneal Dissemination and Invasion.
    Cancer Res. 2007;67:1670-9.
    PubMed     Related articles    Abstract available
    
    
    
66. HANSEN JE , Fischer LK, Chan G, Chang SS, et al
    Antibody-mediated p53 protein therapy prevents liver metastasis in vivo.
    Cancer Res. 2007;67:1769-74.
    PubMed     Related articles    Abstract available
    
    
    
67. LU C , Bonome T, Li Y, Kamat AA, et al
    Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma.
    Cancer Res. 2007;67:1757-68.
    PubMed     Related articles    Abstract available
    
    
    
68. CARLSTEN M , Bjorkstrom NK, Norell H, Bryceson Y, et al
    DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.
    Cancer Res. 2007;67:1317-25.
    PubMed     Related articles    Abstract available
    
    
    January 2007
69. KULBE H , Thompson R, Wilson JL, Robinson S, et al
    The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells.
    Cancer Res. 2007;67:585-92.
    PubMed     Related articles    Abstract available
    
    
    
70. SINGH AP , Chaturvedi P, Batra SK
    Emerging roles of MUC4 in cancer: a novel target for diagnosis and therapy.
    Cancer Res. 2007;67:433-6.
    PubMed     Related articles    Abstract available
    
    
    
71. KAMAT AA , Kim TJ, Landen CN Jr, Lu C, et al
    Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer.
    Cancer Res. 2007;67:281-8.
    PubMed     Related articles    Abstract available
    
    
    
72. PERSSON M , Gedda L, Lundqvist H, Tolmachev V, et al
    [177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts.
    Cancer Res. 2007;67:326-31.
    PubMed     Related articles    Abstract available
    
    
    December 2006
73. CRISTIANO BE , Chan JC, Hannan KM, Lundie NA, et al
    A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition.
    Cancer Res. 2006;66:11718-25.
    PubMed     Related articles    Abstract available
    
    
    November 2006
74. CHEUNG LW , Leung PC, Wong AS
    Gonadotropin-Releasing Hormone Promotes Ovarian Cancer Cell Invasiveness through c-Jun NH2-Terminal Kinase-Mediated Activation of Matrix Metalloproteinase (MMP)-2 and MMP-9.
    Cancer Res. 2006;66:10902-10910.
    PubMed     Related articles    Abstract available
    
    
    
75. HOLZER AK , Howell SB
    The internalization and degradation of human copper transporter 1 following cisplatin exposure.
    Cancer Res. 2006;66:10944-52.
    PubMed     Related articles    Abstract available
    
    
    
76. DENKERT C , Budczies J, Kind T, Weichert W, et al
    Mass Spectrometry-Based Metabolic Profiling Reveals Different Metabolite Patterns in Invasive Ovarian Carcinomas and Ovarian Borderline Tumors.
    Cancer Res. 2006;66:10795-10804.
    PubMed     Related articles    Abstract available
    
    
    
77. CASTELLANO G , Reid JF, Alberti P, Carcangiu ML, et al
    New Potential Ligand-Receptor Signaling Loops in Ovarian Cancer Identified in Multiple Gene Expression Studies.
    Cancer Res. 2006;.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
78. PETROCCA F , Iliopoulos D, Qin HR, Nicoloso MS, et al
    Alterations of the Tumor Suppressor Gene ARLTS1 in Ovarian Cancer.
    Cancer Res. 2006;66:10287-91.
    PubMed     Related articles    Abstract available
    
    
    October 2006
79. SONG H , Ramus SJ, Shadforth D, Quaye L, et al
    Common Variants in RB1 Gene and Risk of Invasive Ovarian Cancer.
    Cancer Res. 2006;66:10220-6.
    PubMed     Related articles    Abstract available
    
    
    
80. PASTORINO F , Brignole C, Di Paolo D, Nico B, et al
    Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
    Cancer Res. 2006;66:10073-82.
    PubMed     Related articles    Abstract available
    
    
    September 2006
81. PEJOVIC T , Yates JE, Liu HY, Hays LE, et al
    Cytogenetic instability in ovarian epithelial cells from women at risk of ovarian cancer.
    Cancer Res. 2006;66:9017-25.
    PubMed     Related articles    Abstract available
    
    
    
82. LEYTON J , Lockley M, Aerts JL, Baird SK, et al
    Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography imaging.
    Cancer Res. 2006;66:9178-85.
    PubMed     Related articles    Abstract available
    
    
    
83. BLASI MF , Ventura I, Aquilina G, Degan P, et al
    A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene.
    Cancer Res. 2006;66:9036-44.
    PubMed     Related articles    Abstract available
    
    
    
84. XING D , Orsulic S
    A mouse model for the molecular characterization of brca1-associated ovarian carcinoma.
    Cancer Res. 2006;66:8949-53.
    PubMed     Related articles    Abstract available
    
    
    
85. SUNDE JS , Donninger H, Wu K, Johnson ME, et al
    Expression Profiling Identifies Altered Expression of Genes That Contribute to the Inhibition of Transforming Growth Factor-{beta} Signaling in Ovarian Cancer.
    Cancer Res. 2006;66:8404-12.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    August 2006
86. KIM KS , Sengupta S, Berk M, Kwak YG, et al
    Hypoxia Enhances Lysophosphatidic Acid Responsiveness in Ovarian Cancer Cells and Lysophosphatidic Acid Induces Ovarian Tumor Metastasis In vivo.
    Cancer Res. 2006;66:7983-90.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    July 2006
87. YANG R , Cai Z, Zhang Y, Yutzy WH 4th, et al
    CD80 in Immune Suppression by Mouse Ovarian Carcinoma-Associated Gr-1+CD11b+ Myeloid Cells.
    Cancer Res. 2006;66:6807-15.
    PubMed     Related articles    Abstract available
    
    
    June 2006
88. PARK JT , Li M, Nakayama K, Mao TL, et al
    Notch3 gene amplification in ovarian cancer.
    Cancer Res. 2006;66:6312-8.
    PubMed     Related articles    Abstract available
    
    
    
89. NORELL H , Carlsten M, Ohlum T, Malmberg KJ, et al
    Frequent Loss of HLA-A2 Expression in Metastasizing Ovarian Carcinomas Associated with Genomic Haplotype Loss and HLA-A2-Restricted HER-2/neu-Specific Immunity.
    Cancer Res. 2006;66:6387-94.
    PubMed     Related articles    Abstract available
    
    
    
90. NARITA K , Staub J, Chien J, Meyer K, et al
    HSulf-1 inhibits angiogenesis and tumorigenesis in vivo.
    Cancer Res. 2006;66:6025-32.
    PubMed     Related articles    Abstract available
    
    
    
91. ABBOSH PH , Montgomery JS, Starkey JA, Novotny M, et al
    Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells.
    Cancer Res. 2006;66:5582-91.
    PubMed     Related articles    Abstract available
    
    
    May 2006
92. GRITZAPIS AD , Mahaira LG, Perez SA, Cacoullos NT, et al
    Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo.
    Cancer Res. 2006;66:5452-60.
    PubMed     Related articles    Abstract available
    
    
    
93. NAKANISHI T , Bailey-Dell KJ, Hassel BA, Shiozawa K, et al
    Novel 5' untranslated region variants of BCRP mRNA are differentially expressed in drug-selected cancer cells and in normal human tissues: implications for drug resistance, tissue-specific expression, and alternative promoter usage.
    Cancer Res. 2006;66:5007-11.
    PubMed     Related articles    Abstract available
    
    
    
94. LUDWIG JA , Szakacs G, Martin SE, Chu BF, et al
    Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.
    Cancer Res. 2006;66:4808-15.
    PubMed     Related articles    Abstract available
    
    
    
95. ZHANG L , Huang J, Yang N, Liang S, et al
    Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKC{iota} as a Biomarker and Potential Oncogene in Ovarian Carcinoma.
    Cancer Res. 2006;66:4627-4635.
    PubMed     Related articles    Abstract available
    
    
    April 2006
96. SUBRAMANIAN IV , Bui Nguyen TM, Truskinovsky AM, Tolar J, et al
    Adeno-Associated Virus-Mediated Delivery of a Mutant Endostatin in Combination with Carboplatin Treatment Inhibits Orthotopic Growth of Ovarian Cancer and Improves Long-term Survival.
    Cancer Res. 2006;66:4319-28.
    PubMed     Related articles    Abstract available
    
    
    
97. ORLOVA A , Magnusson M, Eriksson TL, Nilsson M, et al
    Tumor imaging using a picomolar affinity HER2 binding affibody molecule.
    Cancer Res. 2006;66:4339-48.
    PubMed     Related articles    Abstract available
    
    
    
98. CHOI JH , Choi KC, Auersperg N, Leung PC, et al
    Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells.
    Cancer Res. 2006;66:3912-20.
    PubMed     Related articles    Abstract available
    
    
    
99. KELLY MG , Alvero AB, Chen R, Silasi DA, et al
    TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer.
    Cancer Res. 2006;66:3859-68.
    PubMed     Related articles    Abstract available
    
    
    
100. BAZZARO M , Lee MK, Zoso A, Stirling WL, et al
     Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.
     Cancer Res. 2006;66:3754-63.
     PubMed     Related articles    Abstract available
     
     
     
101. SPOELSTRA NS , Manning NG, Higashi Y, Darling D, et al
     The transcription factor ZEB1 is aberrantly expressed in aggressive uterine cancers.
     Cancer Res. 2006;66:3893-902.
     PubMed     Related articles    Abstract available
     
     
     
102. MACOR P , Mezzanzanica D, Cossetti C, Alberti P, et al
     Complement activated by chimeric anti-folate receptor antibodies is an efficient effector system to control ovarian carcinoma.
     Cancer Res. 2006;66:3876-83.
     PubMed     Related articles    Abstract available
     
     
     
103. XUAN JA , Schneider D, Toy P, Lin R, et al
     Antibodies neutralizing hepsin protease activity do not impact cell growth but inhibit invasion of prostate and ovarian tumor cells in culture.
     Cancer Res. 2006;66:3611-9.
     PubMed     Related articles    Abstract available
     
     
     
104. VILGELM A , Lian Z, Wang H, Beauparlant SL, et al
     Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice.
     Cancer Res. 2006;66:3375-80.
     PubMed     Related articles    Abstract available
     
     
     March 2006
105. VILLANI MG , Appierto V, Cavadini E, Bettiga A, et al
     4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
     Cancer Res. 2006;66:3238-47.
     PubMed     Related articles    Abstract available
     
     
     
106. BALKWILL FR , Ashworth A, Bast RC, Berek JS, et al
     10th Biennial Helene Harris Memorial Trust meeting.
     Cancer Res. 2006;66:2904-6.
     PubMed     Related articles    Abstract available
     
     
     February 2006
107. HICKSON JA , Huo D, Vander Griend DJ, Lin A, et al
     The p38 Kinases MKK4 and MKK6 Suppress Metastatic Colonization in Human Ovarian Carcinoma.
     Cancer Res. 2006;66:2264-70.
     PubMed     Related articles    Abstract available
     
     
     
108. BOERBOOM D , White LD, Dalle S, Courty J, et al
     Dominant-stable beta-catenin expression causes cell fate alterations and Wnt signaling antagonist expression in a murine granulosa cell tumor model.
     Cancer Res. 2006;66:1964-73.
     PubMed     Related articles    Abstract available
     
     
     
109. ERKANLI A , Taylor DD, Dean D, Eksir F, et al
     Application of Bayesian Modeling of Autologous Antibody Responses against Ovarian Tumor-Associated Antigens to Cancer Detection.
     Cancer Res. 2006;66:1792-8.
     PubMed     Related articles    Abstract available
     
     
     
110. BILSLAND AE , Stevenson K, Atkinson S, Kolch W, et al
     Transcriptional repression of telomerase RNA gene expression by c-Jun-NH2-kinase and Sp1/Sp3.
     Cancer Res. 2006;66:1363-70.
     PubMed     Related articles    Abstract available
     
     
     
111. HENDRIX ND , Wu R, Kuick R, Schwartz DR, et al
     Fibroblast growth factor 9 has oncogenic activity and is a downstream target of wnt signaling in ovarian endometrioid adenocarcinomas.
     Cancer Res. 2006;66:1354-62.
     PubMed     Related articles    Abstract available
     
     

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: